Search results for "dose-response"

showing 3 items of 1423 documents

Ultracentrifugation studies on the native form of the first component of human complement (C1)

1976

Dose-Response Relationship DrugChemistryBiophysicsCell BiologyComplement System ProteinsBiochemistryComplement (complexity)SolutionsStructure-Activity RelationshipBiochemistryStructural BiologyComplement C1Component (UML)GeneticsHumansUltracentrifugeMolecular BiologyUltracentrifugationFEBS Letters
researchProduct

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

2007

Abstract The increasing evidence that γδ T cells have potent antitumor activity suggests their value in immunotherapy, particularly in areas of unmet need such as metastatic carcinoma. To this end, we initiated a phase I clinical trial in metastatic hormone-refractory prostate cancer to examine the feasibility and consequences of using the γδ T-cell agonist zoledronate, either alone or in combination with low-dose interleukin 2 (IL-2), to activate peripheral blood γδ cells. Nine patients were enlisted to each arm. Neither treatment showed appreciable toxicity. Most patients were treated with zoledronate + IL-2, but conversely only two treated with zoledronate displayed a significant long-te…

Interleukin 2MaleCancer ResearchNeoplasms Hormone-Dependentmedicine.medical_treatmentT cellT-LymphocytesAntineoplastic AgentsLymphocyte ActivationZoledronic AcidArticleMetastatic carcinomaProstate cancerAntigenMedicineHumansAgedAged 80 and overSalvage TherapyBone Density Conservation AgentsDiphosphonatesDose-Response Relationship Drugbusiness.industryRemission InductionImidazolesProstatic NeoplasmsReceptors Antigen T-Cell gamma-deltaImmunotherapyMiddle Agedmedicine.diseaseVγ9Vδ2 T cellsZoledronateIL-2Hormone-refractory prostate cancerImmunotherapyCytokinemedicine.anatomical_structureTreatment OutcomeOncologyImmunologyFeasibility StudiesInterleukin-2Tumor necrosis factor alphaDrug Therapy CombinationImmunotherapybusinessmedicine.drug
researchProduct

Time course of asymmetric dimethylarginine (ADMA) and oxidative stress in fructose-hypertensive rats: A model related to metabolic syndrome

2011

Asymmetric dimethylarginine (ADMA) is an endogenous modulator of endothelial function and oxidative stress, and increased levels of this molecule have been reported in some metabolic disorders and cardiovascular diseases. The aim of this work was to analyze the time course of dimethylarginine compounds and oxidative stress levels and the relationship between these and cardiovascular function in fructose-hypertensive rats.90 male Sprague-Dawley rats were randomized into 2 groups, fed for 3 months with standard (C) chow supplemented or not with fructose (F, 60%). After sacrifice at different weeks (W), the aorta and plasma were harvested to assess the vascular and biochemical parameters. Our …

Blood GlucoseMaleTime FactorsVasodilator AgentsNitric Oxide Synthase Type IIBlood Pressure030204 cardiovascular system & hematologymedicine.disease_causeRats Sprague-Dawleychemistry.chemical_compound0302 clinical medicineHeart RateEnzyme InhibitorsAortaComputingMilieux_MISCELLANEOUSMetabolic Syndrome0303 health sciencesOxidase testVasodilationNAD(P)H oxidaseHypertensionCardiology and Cardiovascular Medicinemedicine.medical_specialtyFructoseArginine03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicine.arterymedicineAnimals030304 developmental biologyAortaDose-Response Relationship Drugbusiness.industryVascular diseaseBody WeightNADPH OxidasesFructosemedicine.diseaseRatsDisease Models AnimalOxidative StressEndocrinologychemistryTyrosineMetabolic syndromebusinessAsymmetric dimethylarginineOxidative stressAtherosclerosis
researchProduct